{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:18:53Z","timestamp":1786997933820,"version":"build-2736575974"},"reference-count":34,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T00:00:00Z","timestamp":1201824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1016\/j.vaccine.2007.11.087","type":"journal-article","created":{"date-parts":[[2008,1,15]],"date-time":"2008-01-15T07:36:48Z","timestamp":1200382608000},"page":"947-955","source":"Crossref","is-referenced-by-count":19,"title":["Selection and evaluation of the immunogenicity of protective antigen mutants as anthrax vaccine candidates"],"prefix":"10.1016","volume":"26","author":[{"given":"Ming","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Roehrl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emre","family":"Basar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia Y.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2007.11.087_bib1","series-title":"The anthrax vaccine. Is it safe? Does it work?","year":"2002"},{"issue":"5","key":"10.1016\/j.vaccine.2007.11.087_bib2","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0966-842X(00)01755-8","article-title":"Discovery of the anthrax toxin: the beginning of in vivo studies on pathogenic bacteria","volume":"8","author":"Smith","year":"2000","journal-title":"Trends Microbiol"},{"issue":"6","key":"10.1016\/j.vaccine.2007.11.087_bib3","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1128\/IAI.73.6.3408-3414.2005","article-title":"Combining anthrax vaccine and therapy: a dominant-negative inhibitor of anthrax toxin is also a potent and safe immunogen for vaccines","volume":"73","author":"Aulinger","year":"2005","journal-title":"Infect Immun"},{"issue":"19","key":"10.1016\/j.vaccine.2007.11.087_bib4","doi-asserted-by":"crossref","first-page":"10925","DOI":"10.1073\/pnas.1834478100","article-title":"A dually active anthrax vaccine that confers protection against both bacilli and toxins","volume":"100","author":"Rhie","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2007.11.087_bib5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1146\/annurev.cellbio.19.111301.140655","article-title":"Anthrax toxin","volume":"19","author":"Collier","year":"2003","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"5589","key":"10.1016\/j.vaccine.2007.11.087_bib6","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1126\/science.1073163","article-title":"Macrophage apoptosis by anthrax lethal factor through p38 MAP kinase inhibition","volume":"297","author":"Park","year":"2002","journal-title":"Science"},{"issue":"6946","key":"10.1016\/j.vaccine.2007.11.087_bib7","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nature01794","article-title":"Impairment of dendritic cells and adaptive immunity by anthrax lethal toxin","volume":"424","author":"Agrawal","year":"2003","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.vaccine.2007.11.087_bib8","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1073\/pnas.79.10.3162","article-title":"Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells","volume":"79","author":"Leppla","year":"1982","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6860","key":"10.1016\/j.vaccine.2007.11.087_bib9","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/n35101999","article-title":"Identification of the cellular receptor for anthrax toxin","volume":"414","author":"Bradley","year":"2001","journal-title":"Nature"},{"issue":"36","key":"10.1016\/j.vaccine.2007.11.087_bib10","doi-asserted-by":"crossref","first-page":"13147","DOI":"10.1073\/pnas.0405405101","article-title":"Structure of heptameric protective antigen bound to an anthrax toxin receptor: a role for receptor in pH-dependent pore formation","volume":"101","author":"Lacy","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"issue":"21","key":"10.1016\/j.vaccine.2007.11.087_bib11","doi-asserted-by":"crossref","first-page":"10277","DOI":"10.1073\/pnas.89.21.10277","article-title":"Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin","volume":"89","author":"Klimpel","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"10.1016\/j.vaccine.2007.11.087_bib12","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1046\/j.1462-5822.2000.00052.x","article-title":"Proteolytic activation of receptor-bound anthrax protective antigen on macrophages promotes its internalization","volume":"2","author":"Beauregard","year":"2000","journal-title":"Cell Microbiol"},{"issue":"6","key":"10.1016\/j.vaccine.2007.11.087_bib13","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1128\/JB.183.6.2111-2116.2001","article-title":"Involvement of domain 3 in oligomerization by the protective antigen moiety of anthrax toxin","volume":"183","author":"Mogridge","year":"2001","journal-title":"J Bacteriol"},{"issue":"10","key":"10.1016\/j.vaccine.2007.11.087_bib14","doi-asserted-by":"crossref","first-page":"7045","DOI":"10.1073\/pnas.052160199","article-title":"The lethal and edema factors of anthrax toxin bind only to oligomeric forms of the protective antigen","volume":"99","author":"Mogridge","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5517","key":"10.1016\/j.vaccine.2007.11.087_bib15","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1126\/science.109563","article-title":"Dominant-negative mutants of a toxin subunit: an approach to therapy of anthrax","volume":"292","author":"Sellman","year":"2001","journal-title":"Science"},{"issue":"7002","key":"10.1016\/j.vaccine.2007.11.087_bib16","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/nature02763","article-title":"Crystal structure of a complex between anthrax toxin and its host cell receptor","volume":"430","author":"Santelli","year":"2004","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.vaccine.2007.11.087_bib17","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1371\/journal.ppat.0020111","article-title":"Anthrax toxin receptor 2-dependent lethal toxin killing in vivo","volume":"2","author":"Scobie","year":"2006","journal-title":"PLoS Pathog"},{"issue":"6","key":"10.1016\/j.vaccine.2007.11.087_bib18","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.cell.2005.12.045","article-title":"The LDL receptor-related protein LRP6 mediates internalization and lethality of anthrax toxin","volume":"124","author":"Wei","year":"2006","journal-title":"Cell"},{"issue":"47","key":"10.1016\/j.vaccine.2007.11.087_bib19","doi-asserted-by":"crossref","first-page":"39417","DOI":"10.1074\/jbc.M509049200","article-title":"Whole-cell voltage clamp measurements of anthrax toxin pore current","volume":"280","author":"Wolfe","year":"2005","journal-title":"J Biol Chem"},{"issue":"37","key":"10.1016\/j.vaccine.2007.11.087_bib20","doi-asserted-by":"crossref","first-page":"13278","DOI":"10.1073\/pnas.0505865102","article-title":"Receptor-specific requirements for anthrax toxin delivery into cells","volume":"102","author":"Rainey","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"24","key":"10.1016\/j.vaccine.2007.11.087_bib21","doi-asserted-by":"crossref","first-page":"13803","DOI":"10.1073\/pnas.2436299100","article-title":"Mapping dominant-negative mutations of anthrax protective antigen by scanning mutagenesis","volume":"100","author":"Mourez","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"10.1016\/j.vaccine.2007.11.087_bib22","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1084\/jem.20041557","article-title":"Anthrax toxins suppress T lymphocyte activation by disrupting antigen receptor signaling","volume":"201","author":"Paccani","year":"2005","journal-title":"J Exp Med"},{"issue":"12","key":"10.1016\/j.vaccine.2007.11.087_bib23","doi-asserted-by":"crossref","first-page":"8275","DOI":"10.1128\/IAI.73.12.8275-8281.2005","article-title":"Direct inhibition of T-lymphocyte activation by anthrax toxins in vivo","volume":"73","author":"Comer","year":"2005","journal-title":"Infect Immun"},{"issue":"10","key":"10.1016\/j.vaccine.2007.11.087_bib24","doi-asserted-by":"crossref","first-page":"6155","DOI":"10.4049\/jimmunol.176.10.6155","article-title":"Anthrax lethal toxin has direct and potent inhibitory effects on B cell proliferation and immunoglobulin production","volume":"176","author":"Fang","year":"2006","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2007.11.087_bib25","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.coi.2003.11.011","article-title":"Class II MHC peptide loading by the professionals","volume":"16","author":"Bryant","year":"2004","journal-title":"Curr Opin Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2007.11.087_bib26","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1083\/jcb.200312072","article-title":"Membrane insertion of anthrax protective antigen and cytoplasmic delivery of lethal factor occur at different stages of the endocytic pathway","volume":"166","author":"Abrami","year":"2004","journal-title":"J Cell Biol"},{"issue":"1","key":"10.1016\/j.vaccine.2007.11.087_bib27","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1476-9433-4-4","article-title":"Anthrax vaccine design: strategies to achieve comprehensive protection against spore, bacillus, and toxin","volume":"4","author":"Wang","year":"2005","journal-title":"Med Immunol"},{"key":"10.1016\/j.vaccine.2007.11.087_bib28","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.M611142200","article-title":"Selection of anthrax toxin protective antigen variants that discriminate between the cellular receptors TEM8 and CMG2 and achieve targeting of tumor cells","author":"Chen","year":"2007","journal-title":"J Biol Chem"},{"issue":"6619","key":"10.1016\/j.vaccine.2007.11.087_bib29","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/385833a0","article-title":"Crystal structure of the anthrax toxin protective antigen","volume":"385","author":"Petosa","year":"1997","journal-title":"Nature"},{"issue":"33","key":"10.1016\/j.vaccine.2007.11.087_bib30","doi-asserted-by":"crossref","first-page":"30936","DOI":"10.1074\/jbc.M301154200","article-title":"Alanine-scanning mutations in domain 4 of anthrax toxin protective antigen reveal residues important for binding to the cellular receptor and to a neutralizing monoclonal antibody","volume":"278","author":"Rosovitz","year":"2003","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.vaccine.2007.11.087_bib31","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.bbrc.2006.01.080","article-title":"The 2beta2-2beta3 loop of anthrax protective antigen contains a dominant neutralizing epitope","volume":"341","author":"Zhang","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"10.1016\/j.vaccine.2007.11.087_bib32","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/j.1574-695X.2006.00114.x","article-title":"Production and characterization of neutralizing monoclonal antibodies that recognize an epitope in domain 2 of Bacillus anthracis protective antigen","volume":"47","author":"Gubbins","year":"2006","journal-title":"FEMS Immunol Med Microbiol"},{"issue":"11","key":"10.1016\/j.vaccine.2007.11.087_bib33","doi-asserted-by":"crossref","first-page":"6313","DOI":"10.1128\/IAI.72.11.6313-6317.2004","article-title":"Functional analysis of Bacillus anthracis protective antigen by using neutralizing monoclonal antibodies","volume":"72","author":"Brossier","year":"2004","journal-title":"Infect Immun"},{"issue":"Pt 3","key":"10.1016\/j.vaccine.2007.11.087_bib34","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1099\/13500872-142-3-707","article-title":"Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies","volume":"142","author":"Little","year":"1996","journal-title":"Microbiology"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X07014405?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X07014405?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T09:22:42Z","timestamp":1546334562000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X07014405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["S0264410X07014405"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2007.11.087","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2008,2]]}}}